Adile Orhan

Ms. Adile Orhan

Department of Surgery, Zealand University Hospital Køge, Køge, Denmark
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
HRHans Henrik Raskov
Hans Henrik Raskov
Adile OrhanAdile Orhan
Adile Orhan
JCJan Pravsgaard Christensen
Jan Pravsgaard Christensen
IGIsmail Gögenur
Ismail Gögenur
The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.

1 June 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
Adile OrhanAdile Orhan
Adile Orhan
RVRasmus P. Vogelsang
Rasmus P. Vogelsang
MAMalene B. Andersen
Malene B. Andersen
MMMichael Tvilling Madsen
Michael Tvilling Madsen
EHEmma R. Hölmich
Emma R. Hölmich
IGIsmail Gögenur
Ismail Gögenur

20 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HRHans Henrik Raskov
Hans Henrik Raskov
Adile OrhanAdile Orhan
Adile Orhan
SGShruti Gaggar
Shruti Gaggar
IGIsmail Gögenur
Ismail Gögenur
Our understanding of the tumor microenvironment (TME), including the interplay between tumor cells, stromal cells, immune cells, and extracellular matrix components, is mandatory for the innovation of new therapeutic approaches in cancer. The cell-cell communication within the TME plays a pivotal role in the evolution and progression of cancer. Cancer-associated fibroblasts (CAF) and tumor-associated macrophages (TAM) are major cell populations in the stroma of all solid tumors and often exert protumorigenic functions; however, the origin and precise functions of CAF and TAM are still incompletely understood. CAF and TAM hold significant potential as therapeutic targets to improve outcomes in oncology when combined with existing therapies. The regulation of CAF/TAM communication and/or their differentiation could be of high impact for improving the future targeted treatment strategies. Nevertheless, there is much scope for research and innovation in this field with regards to the development of novel drugs. In this review, we elaborate on the current knowledge on CAF and TAM in cancer and cancer immunotherapy. Additionally, by focusing on their heterogenous functions in different stages and types of cancer, we explore their role as potential therapeutic targets and highlight certain aspects of their functions that need further research.

3 May 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
HRHans Henrik Raskov
Hans Henrik Raskov
Adile OrhanAdile Orhan
Adile Orhan
SGShruti Gaggar
Shruti Gaggar
IGIsmail Gögenur
Ismail Gögenur
Neutrophils are central mediators of innate and adaptive immunity and first responders to tissue damage. Although vital to our health, their activation, function, and resolution are critical to preventing chronic inflammation that may contribute to carcinogenesis. Cancers are associated with the expansion of the neutrophil compartment with an escalation in the number of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in the peripheral circulation and tumor microenvironment. Although phenotypically similar to classically activated neutrophils, PMN-MDSC is pathologically activated and immunosuppressive in nature. They dynamically interact with other cell populations and tissue components and convey resistance to anticancer therapies while accelerating disease progression and metastatic spread. Cancer-associated neutrophilia and tumor infiltration of neutrophils are significant markers of poor outcomes in many cancers. Recently, there has been significant progress in the identification of molecular markers of PMN-MDSC providing insights into the central role of PMN-MDSC in the local tumor microenvironment as well as the systemic immune response in cancer. Further advances in sequencing and proteomics techniques will improve our understanding of their diverse functionalities and the complex molecular mechanisms at play. Targeting PMN-MDSC is currently one of the major focus areas in cancer research and several signaling pathways representing possible treatment targets have been identified. Positive results from preclinical studies clearly justify the current investigation in drug development and thus novel therapeutic strategies are being evaluated in clinical trials. In this review, we discuss the involvement of PMN-MDSC in cancer initiation and progression and their potential as therapeutic targets and clinical biomarkers in different cancers.

10 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TJTobias Freyberg Justesen
Tobias Freyberg Justesen
Adile OrhanAdile Orhan
Adile Orhan
HRHans Henrik Raskov
Hans Henrik Raskov
CNChristian Pállson Nolsøe
Christian Pállson Nolsøe
Ismail GögenurIsmail Gögenur
Ismail Gögenur
The discovery of electroporation in 1968 has led to the development of electrochemotherapy (ECT) and irreversible electroporation (IRE). ECT and IRE have been established as treatments of cutaneous and subcutaneous tumors and locally advanced pancreatic cancer, respectively. Interestingly, the treatment modalities have been shown to elicit immunogenic cell death, which in turn can induce an immune response towards the tumor cells. With the dawn of the immunotherapy era, the potential of combining ECT and IRE with immunotherapy has led to the launch of numerous studies. Data from the first clinical trials are promising, and new combination regimes might change the way we treat tumors characterized by low immunogenicity and high levels of immunosuppression, such as melanoma and pancreatic cancer. In this review we will give an introduction to ECT and IRE and discuss the impact on the immune system. Additionally, we will present the results of clinical and preclinical trials, investigating the combination of electroporation modalities and immunotherapy.

1 November 2021 in Cancer Letters
Verified
Journal Article
Closed access
HRHans Henrik Raskov
Hans Henrik Raskov
Adile OrhanAdile Orhan
Adile Orhan
ASAli salanti
Ali salanti
SGShruti Gaggar
Shruti Gaggar
Ismail GögenurIsmail Gögenur
Ismail Gögenur